Lymphodepletional strategies in transplantation.

Because lymphocytes were shown to mediate transplant rejection, their depletion has been studied as a mechanism of preventing rejection and perhaps inducing immunologic tolerance. Agents that profoundly deplete lymphocytes have included monoclonal antibodies, cytotoxic drugs, and radiation. We have studied several such agents but focused on antibodies that deplete not only peripheral blood lymphocytes, but also lymph node lymphocytes. Depletion of lymph node T lymphocytes appears to permit peripheral tolerance at least for T cells in animal models. Nevertheless, B-cell responses may be resistant to such approaches, and T memory cells are likewise relatively resistant to depleting antibodies. We review the experimental and clinical approaches to depletion strategies and outline some of the pitfalls of depletion, such as limitations of currently available agents, duration of tolerance, infection, and malignancy. It is notable that most tolerogenic strategies that have been attempted experimentally and clinically include depleting agents even when they are not named as the underlying strategy. Thus, there is an implicitly acknowledged role for reducing the precursor frequency of donor antigen-specific lymphocytes when approaching the daunting goal of transplant tolerance.

[1]  W. Chapman,et al.  Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  S. Knechtle,et al.  Patterns of De Novo Allo B Cells and Antibody Formation in Chronic Cardiac Allograft Rejection After Alemtuzumab Treatment , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  G. Lal,et al.  NK Cells are Required for Costimulatory Blockade Induced Tolerance to Vascularized Allografts , 2012, Transplantation.

[4]  S. Knechtle,et al.  Enhanced De Novo Alloantibody and Antibody‐Mediated Injury in Rhesus Macaques , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  M. Ruzek,et al.  Transient Low-Dose Methotrexate Induces Tolerance to Murine Anti-Thymocyte Globulin and Together They Promote Long-Term Allograft Survival , 2012, The Journal of Immunology.

[6]  A. Kirk,et al.  Alternative Immunomodulatory Strategies for Xenotransplantation: CD40/154 Pathway‐Sparing Regimens Promote Xenograft Survival , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  D. Scott,et al.  Endogenous Expansion of Regulatory T Cells Leads to Long‐Term Islet Graft Survival in Diabetic NOD Mice , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  S. Knechtle,et al.  The role of B cells in solid organ transplantation. , 2012, Seminars in immunology.

[9]  S. Strober,et al.  Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants. , 2012, Blood.

[10]  R. Colvin,et al.  A Novel Pathway of Chronic Allograft Rejection Mediated by NK Cells and Alloantibody , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  D. Sachs,et al.  Development of a diphtheria toxin based antiporcine CD3 recombinant immunotoxin. , 2011, Bioconjugate chemistry.

[12]  R. Redfield,et al.  Essential role for B cells in transplantation tolerance. , 2011, Current opinion in immunology.

[13]  D. Sachs,et al.  First Experience With the Use of a Recombinant CD3 Immunotoxin as Induction Therapy in Pig-to-Primate Xenotransplantation: The Effect of T-Cell Depletion on Outcome , 2011, Transplantation.

[14]  S. Mulgaonkar,et al.  Alemtuzumab induction in renal transplantation. , 2011, The New England journal of medicine.

[15]  P. Friend,et al.  Th17 Cells in Alemtuzumab-Treated Patients: The Effect of Long-Term Maintenance Immunosuppressive Therapy , 2011, Transplantation.

[16]  S. Crotty,et al.  Follicular helper CD4 T cells (TFH). , 2011, Annual review of immunology.

[17]  A. Monaco,et al.  25 Years and New Frontiers in Solid Organ Transplantation and Haematology , 2011 .

[18]  T. Coffman,et al.  B Lymphocytes Differentially Influence Acute and Chronic Allograft Rejection in Mice , 2011, The Journal of Immunology.

[19]  S. Soker,et al.  Clinical Operational Tolerance After Renal Transplantation: Current Status and Future Challenges , 2010, Annals of surgery.

[20]  J. Brenchley,et al.  Lineage-specific T-cell reconstitution following in vivo CD4+ and CD8+ lymphocyte depletion in nonhuman primates. , 2010, Blood.

[21]  C. Klein,et al.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.

[22]  E. Morelon,et al.  Preferential increase in memory and regulatory subsets during T-lymphocyte immune reconstitution after Thymoglobulin induction therapy with maintenance sirolimus vs cyclosporine. , 2010, Transplant immunology.

[23]  R. Pierson,et al.  Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys. , 2010, The Journal of clinical investigation.

[24]  J. Ijzermans,et al.  Investigation of Lymphocyte Depletion and Repopulation Using Alemtuzumab (Campath‐1H) in Cynomolgus Monkeys , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  J. Dumortier,et al.  Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: A five‐year randomized prospective study , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[26]  J. Fechner,et al.  BAFF Is Increased in Renal Transplant Patients Following Treatment with Alemtuzumab , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  M. Ban,et al.  IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). , 2009, The Journal of clinical investigation.

[28]  Kenneth G. C. Smith,et al.  B-cell-depleting induction therapy and acute cellular rejection. , 2009, The New England journal of medicine.

[29]  D. San Segundo,et al.  Changes in the serum levels of interleukin‐17/interleukin‐23 during acute rejection in liver transplantation , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[30]  J. Desjarlais,et al.  The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. , 2009, Blood.

[31]  G. Verleden,et al.  The Role of the IL23/IL17 Axis in Bronchiolitis Obliterans Syndrome After Lung Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[32]  C. Hunter,et al.  With a little help from their friends: interleukin-21, T cells, and B cells. , 2008, Immunity.

[33]  C. Drachenberg,et al.  Thymoglobulin Dose Optimization for Induction Therapy in High Risk Kidney Transplant Recipients , 2008, Transplantation.

[34]  Eric Vivier,et al.  Functions of natural killer cells , 2008, Nature Immunology.

[35]  T. Starzl,et al.  Alemtuzumab Preconditioning With Tacrolimus Monotherapy—The Impact of Serial Monitoring for Donor-Specific Antibody , 2008, Transplantation.

[36]  Yong Zhao,et al.  Depleting Anti-CD4 Monoclonal Antibody (GK1.5) Treatment: Influence on Regulatory CD4+CD25+Foxp3+ T Cells in Mice , 2008, Transplantation.

[37]  J. Fechner,et al.  CD4+CD25+FOXP3+ Regulatory T Cells Increase De Novo in Kidney Transplant Patients After Immunodepletion with Campath‐1H , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[38]  A. Monaco,et al.  SV40 Infection Associated With Rituximab Treatment After Kidney Transplantation in Nonhuman Primates , 2008, Transplantation.

[39]  Thomas F. Tedder,et al.  Maintenance of Long-Lived Plasma Cells and Serological Memory Despite Mature and Memory B Cell Depletion during CD20 Immunotherapy in Mice1 , 2008, The Journal of Immunology.

[40]  A. Vats,et al.  Alemtuzumab Pre‐Conditioning With Tacrolimus Monotherapy in Pediatric Renal Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[41]  P. Munson,et al.  Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. , 2007, Blood.

[42]  M. Rickels,et al.  B lymphocyte–directed immunotherapy promotes long-term islet allograft survival in nonhuman primates , 2007, Nature Medicine.

[43]  A. Kirk,et al.  Dissociation of Depletional Induction and Posttransplant Lymphoproliferative Disease in Kidney Recipients Treated With Alemtuzumab , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[44]  D. Neville,et al.  A fold-back single-chain diabody format enhances the bioactivity of an anti-monkey CD3 recombinant diphtheria toxin-based immunotoxin. , 2007, Protein engineering, design & selection : PEDS.

[45]  M. Mohty,et al.  Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond , 2007, Leukemia.

[46]  A. Kirk,et al.  CD154 Blockade, Sirolimus, and Donor-Specific Transfusion Prevents Renal Allograft Rejection in Cynomolgus Monkeys Despite Homeostatic T-Cell Activation , 2007, Transplantation.

[47]  R. Colvin,et al.  Depletion of CD8 Memory T Cells for Induction of Tolerance of a Previously Transplanted Kidney Allograft , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[48]  D. Danilenko,et al.  Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade. , 2007, Blood.

[49]  K. Hardinger,et al.  Rabbit Antithymocyte Globulin Induction Therapy in Adult Renal Transplantation , 2006, Pharmacotherapy.

[50]  D. Brennan,et al.  Rabbit antithymocyte globulin versus basiliximab in renal transplantation. , 2006, The New England journal of medicine.

[51]  P. Friend,et al.  Recipient Memory-Like Lymphocytes Remain Unresponsive to Graft Antigens After CAMPATH-1H Induction with Reduced Maintenance Immunosuppression , 2006, Transplantation.

[52]  S. Knechtle,et al.  The evolving role of alemtuzumab (Campath‐1H) for immunosuppressive therapy in organ transplantation , 2006, Transplant international : official journal of the European Society for Organ Transplantation.

[53]  A. Webster,et al.  Monoclonal and Polyclonal Antibody Therapy for Treating Acute Rejection in Kidney Transplant Recipients: A Systematic Review of Randomized Trial Data , 2006, Transplantation.

[54]  J. Markmann,et al.  Accelerated Memory Cell Homeostasis during T Cell Depletion and Approaches to Overcome It , 2006, The Journal of Immunology.

[55]  Shaoming Huang,et al.  Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation , 2006, Transplant International.

[56]  U. Christians,et al.  Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates , 2006, Nature Medicine.

[57]  M. Carrier,et al.  Incidence and prognosis of cancer following heart transplantation using RATG induction therapy , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[58]  Keiji Oi,et al.  Cardiac xenotransplantation: recent preclinical progress with 3-month median survival. , 2005, The Journal of thoracic and cardiovascular surgery.

[59]  J. Gaynor,et al.  A Randomized Trial of Three Renal Transplant Induction Antibodies: Early Comparison of Tacrolimus, Mycophenolate Mofetil, and Steroid Dosing, and Newer Immune-Monitoring1 , 2005, Transplantation.

[60]  Kenneth G. C. Smith,et al.  Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation—Efficacy and Safety at Five Years , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[61]  A. Kirk,et al.  Immunocompetent T‐Cells with a Memory‐Like Phenotype are the Dominant Cell Type Following Antibody‐Mediated T‐Cell Depletion , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[62]  D. Dunn,et al.  Fungal infections in transplant recipients receiving alemtuzumab. , 2005, Transplantation proceedings.

[63]  T. Starzl,et al.  Use of Alemtuzumab and Tacrolimus Monotherapy for Cadaveric Liver Transplantation: With Particular Reference to Hepatitis C Virus , 2004, Transplantation.

[64]  R. Colvin,et al.  CD154 Blockade for Induction of Mixed Chimerism and Prolonged Renal Allograft Survival in Nonhuman Primates , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[65]  R. Bontrop,et al.  Metastable Tolerance to Rhesus Monkey Renal Transplants Is Correlated with Allograft TGF-β1+CD4+ T Regulatory Cell Infiltrates1 , 2004, The Journal of Immunology.

[66]  C. Ricordi,et al.  Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY7201 , 2004, Transplantation.

[67]  G. Jhangri,et al.  Herpes Zoster Infection Following Solid Organ Transplantation: Incidence, Risk Factors and Outcomes in the Current Immunosuppressive Era , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[68]  L. Swinnen,et al.  Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation1 , 2003, Transplantation.

[69]  J. Fechner,et al.  Immunotoxin-treated rhesus monkeys: a model for renal allograft chronic rejection1 , 2003, Transplantation.

[70]  D. Harlan,et al.  RESULTS FROM A HUMAN RENAL ALLOGRAFT TOLERANCE TRIAL EVALUATING THE HUMANIZED CD52‐SPECIFIC MONOCLONAL ANTIBODY ALEMTUZUMAB (CAMPATH‐1H) , 2003, Transplantation.

[71]  D. Harlan,et al.  RABBIT ANTITHYMOCYTE GLOBULIN INDUCTION AND SIROLIMUS MONOTHERAPY SUPPORTS PROLONGED ISLET ALLOGRAFT FUNCTION IN A NONHUMAN PRIMATE ISLET TRANSPLANTATION MODEL , 2003, Transplantation.

[72]  Paulo Fontes,et al.  Tolerogenic immunosuppression for organ transplantation , 2003, The Lancet.

[73]  G. Szot,et al.  CD28/B7 Regulation of Anti-CD3-Mediated Immunosuppression In Vivo1 , 2003, The Journal of Immunology.

[74]  D. Harlan,et al.  Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy , 2002, The Lancet.

[75]  V. Brinkmann,et al.  Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD , 2002, Transplantation.

[76]  A. Aruffo,et al.  Anti-CD40 therapy extends renal allograft survival in rhesus macaques1 , 2002, Transplantation.

[77]  Stephen C. Jameson,et al.  Maintaining the norm: T-cell homeostasis , 2002, Nature Reviews Immunology.

[78]  R. Poropatich,et al.  Hospitalizations for cytomegalovirus disease after renal transplantation in the United States. , 2002, Annals of epidemiology.

[79]  H. Meier‐Kriesche,et al.  Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. , 2002, Journal of the American Society of Nephrology : JASN.

[80]  T. Batiuk,et al.  Infectious disease prophylaxis in renal transplant patients: a survey of US transplant centers , 2002, Clinical transplantation.

[81]  M. Carson,et al.  A Ligand for the Chemokine Receptor CCR7 Can Influence the Homeostatic Proliferation of CD4 T Cells and Progression of Autoimmunity1 , 2001, The Journal of Immunology.

[82]  R. Buelow,et al.  Total and active thymoglobulin levels: effects of dose and sensitization on serum concentrations. , 2001, Transplant immunology.

[83]  Yulian Wu,et al.  A proteasome inhibitor effectively prevents mouse heart allograft rejection. , 2001, Transplantation.

[84]  S. Knechtle Treatment with immunotoxin. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[85]  G. Hale,et al.  The CD52 antigen and development of the CAMPATH antibodies. , 2001, Cytotherapy.

[86]  J. Revillard,et al.  MECHANISMS INVOLVED IN ANTITHYMOCYTE GLOBULIN IMMUNOSUPPRESSIVE ACTIVITY IN A NONHUMAN PRIMATE MODEL 1 , 2001, Transplantation.

[87]  H. Schuurman,et al.  The novel immunosuppressant FTY720 induces peripheral lymphodepletion of both T- and B-cells in cynomolgus monkeys when given alone, with Cyclosporine Neoral or with RAD. , 2000, Transplant immunology.

[88]  J. Bradley,et al.  Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. , 1999, Transplantation.

[89]  H. Schuurman,et al.  A novel immunosuppressant, FTY720, induces peripheral lymphodepletion of both T- and B cells and immunosuppression in baboons. , 1999, Transplant immunology.

[90]  C. Janeway,et al.  Designing and maintaining the mature TCR repertoire: the continuum of self-peptide:self-MHC complex recognition. , 1999, Immunity.

[91]  J. Wain,et al.  In vivo generation of C4d, Bb, iC3b, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients. , 1999, Transplantation.

[92]  N. Armstrong,et al.  Primate renal transplants using immunotoxin. , 1998, Surgery.

[93]  P. Friend,et al.  Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients , 1998, The Lancet.

[94]  B. Sido,et al.  Differential immunosuppressive activity of monoclonal CD2 antibodies on allograft rejection versus specific antibody production , 1998, European journal of immunology.

[95]  M. Béné,et al.  Serum anti-rabbit and anti-horse IgG, IgA, and IgM in kidney transplant recipients. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[96]  D. Neville,et al.  Genetic construction and characterization of an anti-monkey CD3 single-chain immunotoxin with a truncated diphtheria toxin. , 1997, Bioconjugate chemistry.

[97]  R. Buelow,et al.  Characterization of anti-thymoglobulin, anti-Atgam and anti-OKT3 IgG antibodies in human serum with an 11-min ELISA. , 1997, Transplant immunology.

[98]  J. Fechner,et al.  FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. , 1997, Transplantation.

[99]  C. Orosz,et al.  Prevention of murine cardiac allograft rejection with gallium nitrate. Comparison with anti-CD4 monoclonal antibody. , 1996, Transplantation.

[100]  C. Marboe,et al.  Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival. , 1996, Transplantation.

[101]  G. Opelz EFFICACY OF REJECTION PROPHYLAXIS WITH OKT3 IN RENAL TRANSPLANTATION , 1995, Transplantation.

[102]  D. M. Hamlin,et al.  COMPARATIVE POLYCLONAL ANTITHYMOCYTE GLOBULIN AND ANTILYMPHOCYTE/ANTILYMPHOBLAST GLOBULIN ANTI‐CD ANTIGEN ANALYSIS BY FLOW CYTOMETRY , 1995, Transplantation.

[103]  J. Kupiec-Weglinski,et al.  alpha/beta-T cell receptor-directed therapy in rat cardiac allograft recipients. Treatment prior to alloantigen exposure prevents sensitization and abrogates accelerated rejection. , 1995, Transplantation.

[104]  R. Colvin,et al.  Mixed Allogeneic Chimerism And Renal Allograft Tolerance In Cynomolgus Monkeys , 1995, Transplantation.

[105]  J. Thomas,et al.  A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. , 1994, Transplantation.

[106]  K. Wood,et al.  Lymphocyte changes associated with prolongation of cardiac allograft survival in adult mice using anti‐CD4 monoclonal antibody , 1993, Clinical and experimental immunology.

[107]  F. Delmonico,et al.  Nonhuman primate responses to murine and humanized OKT4A. , 1993, Transplantation.

[108]  G. Aversa,et al.  INDUCTION OF LONG‐TERM SPECIFIC TOLERANCE TO ALLOGRAFTS IN RATS BY THERAPY WITH AN ANTI‐CD3-LIKE MONOCLONAL ANTIBODY , 1993, Transplantation.

[109]  J. Bluestone,et al.  Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression. , 1992, Journal of Immunology.

[110]  D. Neville,et al.  In vivo T-cell ablation by a holo-immunotoxin directed at human CD3. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[111]  R. Schooley,et al.  SYMPTOMATIC CYTOMEGALOVIRUS DISEASE IN THE CYTOMEGALOVIRUS ANTIBODY SEROPOSITIVE RENAL TRANSPLANT RECIPIENT TREATED WITH OKT31,2 , 1992, Transplantation.

[112]  S. Rudnick,et al.  OKT3E, AN ANTI‐CD3 ANTIBODY THAT DOES NOT ELICIT SIDE EFFECTS OR ANTIIDIOTYPE RESPONSES IN CHIMPANZEES , 1991, Transplantation.

[113]  J. Gartner,et al.  Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: a growing concern. , 1991, The Journal of pediatrics.

[114]  C. Vincent,et al.  Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. , 1991, Transplantation.

[115]  R. Fisher,et al.  Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. , 1990, The New England journal of medicine.

[116]  I. Penn Cancers complicating organ transplantation. , 1990, The New England journal of medicine.

[117]  R. Colvin,et al.  Prolonged survival of nonhuman primate renal allograft recipients treated only with anti-CD4 monoclonal antibody. , 1990, Surgery.

[118]  C. Ferran,et al.  IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION: SYSTEMIC CYTOKINE RELEASE AND MODULATION BY CORTICOSTEROIDS , 1990, Transplantation.

[119]  K. Leunissen,et al.  EVIDENCE OF INVOLVEMENT OF TUMOR NECROSIS FACTOR IN ADVERSE REACTIONS DURING TREATMENT OF KIDNEY ALLOGRAFT REJECTION WITH ANTITHYMOCYTE GLOBULIN , 1989, Transplantation.

[120]  F. Thomas,et al.  PROMOTION OF INCOMPATIBLE ALLOGRAFT ACCEPTANCE IN RHESUS MONKEYS GIVEN POSTTRANSPLANT ANTITHYMOCYTE GLOBULIN AND DONOR BONE MARROW: II. EFFECTS OF ADJUVANT IMMUNOSUPPRESSIVE DRUGS' , 1989, Transplantation.

[121]  E. Reinherz,et al.  In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates: I. Effects of anti-T11 antibodies on the circulating T cell pool. , 1985, Blood.

[122]  G. Boulianne,et al.  Production of functional chimaeric mouse/human antibody , 1984, Nature.

[123]  S L Morrison,et al.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[124]  J. Thomas,et al.  Long-term incompatible kidney survival in outbred higher primates without chronic immunosuppression. , 1983, Annals of surgery.

[125]  G. Goldstein,et al.  EFFECTS OF IN VIVO ADMINISTRATION OF MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN T CELL SUBPOPULATIONS ON THE IMMUNE SYSTEM IN A RHESUS MONKEY MODEL , 1983, Transplantation.

[126]  E. Reinherz,et al.  Monoclonal antibodies defining distinctive human T cell surface antigens. , 1979, Science.

[127]  J. Najarian,et al.  The clinical use of antilymphocyte globulin. , 1971, The New England journal of medicine.

[128]  T. Starzl,et al.  THE CLINICAL USE OF ANTILYMPHOCYTE GLOBULIN IN RENAL HOMOTRANSPLANTATION , 1967, Transplantation.

[129]  T. Starzl,et al.  THE REVERSAL OF REJECTION IN HUMAN RENAL HOMOGRAFTS WITH SUBSEQUENT DEVELOPMENT OF HOMOGRAFT TOLERANCE. , 1963, Surgery, gynecology & obstetrics.

[130]  Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. , 2012, The Journal of pathology.

[131]  Joan W. Miller,et al.  Long-Term Results of Rabbit Antithymocyte Globulin and Basiliximab Induction , 2008 .

[132]  J. Markmann,et al.  Homeostatic proliferation is a barrier to transplantation tolerance , 2004, Nature Medicine.

[133]  D. Melvin,et al.  Antimurine antibody formation following OKT3 therapy. , 1990, Transplantation.